CymaBay to Report Second Quarter 2017 Financial Results on Thursday, August 10

NEWARK, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. CBAY, a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, August 10^th at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2017 and provide a business update.

Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13667520.  To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events. 

About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC). A Phase 2 study of seladelpar established proof of concept in PBC. CymaBay is currently conducting a second Phase 2 study of seladelpar in PBC in order to support dose selection for Phase 3.

For additional Information about CymaBay visit www.cymabay.com.

Contact:	
Sujal Shah			
CymaBay Therapeutics, Inc.	
(510) 293-8800			
Investors@CymaBay.com	

Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
Hans@LifeSciAdvisors.com